首页> 美国卫生研究院文献>Frontiers in Neurology >The Technique of Endovascular Intracranial Revascularization
【2h】

The Technique of Endovascular Intracranial Revascularization

机译:血管内颅内血运重建技术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Intracranial atherosclerosis was traditionally believed to carry a risk of stroke of 8% to 22% per annum. The annualized stroke rate in the recent stenting and aggressive medical management for preventing stroke in intracranial stenosis (SAMMPRIS) trial medical management arm was 12.2%. This trial was halted due to excessive periprocedural events in the stent arm. This stroke rate is still unacceptably, high and a treatment strategy is still needed. SAMMPRIS has no bearing on angioplasty alone. Angioplasty alone has always been our primary intervention for intracranial atherosclerosis and remains so to this day due to its relative simplicity, low complication rate, and efficacy. We have, however, made adjustments to our patient management regimen based on the results of SAMMPRIS. This paper outlines our current patient selection, procedural technique, and post-procedure management. The complications we have encountered while developing our technique are described along with how to avoid them and how to manage them. Our most recent results (since previous publications) are also discussed.
机译:传统上认为颅内动脉粥样硬化每年有8%至22%的中风风险。在最近的支架置入和积极的药物治疗中,防止颅内狭窄(SAMMPRIS)试验性药物治疗组中风的年发生率是12.2%。由于支架臂过度的围手术期事件,该试验被终止。该中风率仍然是不能接受的,很高并且仍然需要治疗策略。 SAMMPRIS仅与血管成形术无关。单纯血管成形术一直是我们颅内动脉粥样硬化的主要干预手段,并且由于其相对简单,并发症少和疗效高的优势,至今一直如此。但是,我们已根据SAMMPRIS的结果对患者的治疗方案进行了调整。本文概述了我们当前的患者选择,程序技术和术后管理。描述了在开发技术时遇到的复杂性以及如何避免和管理它们。还讨论了我们的最新结果(自以前的出版物以来)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号